StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) income statement

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$0.92−0.06 (-6.39%)

Close on Nov 20, 2026Market cap $92.40MP/E –Yield –

See a number that looks wrong?